The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Updates from the RESTORE trial of elritercept plus ruxolitinib in patients with MF and anemia
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the updated results from the Phase II RESTORE trial (NCT05037760) evaluating elritercept in combination with ruxolitinib in patients with myelofibrosis (MF) and anemia. Prof. Rinaldi highlights the improvements in hematological and clinical parameters, including reduced transfusion requirements, increased hemoglobin levels, and improved platelet counts. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We present the latest data on this very interesting Phase II clinical trial called RESTORE, where we combine a elritercept with ruxolitinib with in patients that were previously on a stable dose of ruxolitinib for at least two months. Those are a group of patients with anemia. We know that anemia is an unmet need in myelofibrosis. Around 40% of the patients have an anemia diagnosis and nearly 80% following the first year of diagnosis...
We present the latest data on this very interesting Phase II clinical trial called RESTORE, where we combine a elritercept with ruxolitinib with in patients that were previously on a stable dose of ruxolitinib for at least two months. Those are a group of patients with anemia. We know that anemia is an unmet need in myelofibrosis. Around 40% of the patients have an anemia diagnosis and nearly 80% following the first year of diagnosis. Treatment currently with JAK inhibitors frontline can make anemia worse in some of those patients, so there is a requirement to perhaps optimize this treatment, which is where elritercept comes in. elritercept is a TGF-beta downstream blocker, so it reestablishes the hemopoiesis in the bone marrow, reduces fibrosis, which translates into an improvement in transfusion requirements, particularly in terms of number of units received over the 12-week period, but also increasing the hemoglobin level as well. And it does have an impact on platelets, you know, patients treated with elritercept and ruxolitinib showed an improvement in platelet count over the 12 weeks exposure, also a further improvement in spleen size and in symptom burden. So it looks very much like this combination could be a potential new treatment in cytopenic patients with myelofibrosis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
